Vector Laboratories, Inc.
Vector Laboratories, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Vector Laboratories, Inc..
Vector Laboratories, Inc. is a company.
Key people at Vector Laboratories, Inc..
Vector Laboratories, Inc. is a biotechnology company founded in 1976 that develops and manufactures innovative reagents and kits for proteomic and glycomic research, serving academic, industrial, and manufacturing scientists worldwide.[1][2][4] It pioneered avidin-biotin enzyme complex kits for immunohistochemistry and antifade mounting media for immunofluorescence, offering over 600 products including those for immunofluorescence, immunohistochemistry, glycobiology, bioconjugation, and custom manufacturing solutions.[1][2] With approximately 99 employees and $21.2 million in revenue, the company targets challenges in cancer research, neuroscience, immunology, and infectious diseases, empowering advances through reliable tools cited in over 350,000 peer-reviewed publications.[1][2][4]
Headquartered in Newark, California, Vector Laboratories supports global researchers via labs and offices in the US, UK, and Europe, bolstered by strategic acquisitions like Click Chemistry Tools, Fluoroprobes, Quanta BioDesign, and a merger with Absolute Biotech to expand its antibody-centric and high-performance offerings.[2][4]
Vector Laboratories was established in 1976 as a pioneer in scientific tools, initially focusing on immunohistochemistry before expanding into labeling, detection, conjugating technologies, immunofluorescence, and glycobiology.[1][2] The company quickly innovated by becoming the first to commercialize avidin-biotin enzyme complex kits and antifade mounting media, building a reputation over nearly five decades as a trusted partner with unmatched technical expertise.[1][2]
Key milestones include strategic acquisitions—Click Chemistry Tools, Fluoroprobes, and Quanta BioDesign—and a recent merger with Absolute Biotech, which broadened its portfolio for life sciences tools, diagnostics, and biotherapeutics.[2][4] This evolution reflects a commitment to growth while maintaining a culture of integrity, excellence, inclusion, and customer relationships, now supporting worldwide scientific industries from its Newark base.[1][2]
Vector Laboratories rides the wave of advancing proteomics, glycomics, and bioconjugation trends critical to precision medicine, including antibody-drug conjugates (ADCs) for targeted cancer therapies and tools for neuroscience and infectious disease research.[2] Its timing aligns with booming demand for high-fidelity reagents in diagnostics, biotherapeutics, and clinical research, fueled by market forces like rising R&D in immunotherapy and personalized medicine.[1][2][4]
The company influences the ecosystem by enabling reproducible results in peer-reviewed studies and SOPs worldwide, accelerating discoveries through custom solutions and acquisitions that fill gaps in labeling/detection tech.[1][2] As a manufacturing partner, it supports the life sciences supply chain, reducing barriers for researchers tackling complex diseases.[4]
Vector Laboratories is poised for continued expansion through its merger-enhanced portfolio, focusing on ADC research, bioconjugates, and custom reagents amid surging biotech innovation.[2][4] Trends like AI-driven drug discovery and federated learning in healthcare (though not core to Vector) will amplify demand for its precise proteomic tools, potentially driving revenue growth beyond $21M via global partnerships.[1][2]
Its influence may evolve as a comprehensive supplier in the biotherapeutics pipeline, solidifying leadership in immunofluorescence and glycobiology while adapting to sustainable manufacturing needs—ultimately empowering more breakthroughs from its foundational mission of scientific curiosity.[1][2][4]
Key people at Vector Laboratories, Inc..